MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Pfizer
University Hospital, Toulouse
University Hospital, Toulouse
Dartmouth-Hitchcock Medical Center
Poitiers University Hospital
Dana-Farber Cancer Institute
Stichting Hemato-Oncologie voor Volwassenen Nederland
University Hospital, Grenoble
Rush University Medical Center
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Amgen
National Heart, Lung, and Blood Institute (NHLBI)
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Novartis
Celgene
M.D. Anderson Cancer Center
Celgene
Gruppo Italiano per lo Studio del Mieloma Multiplo
University of Leeds
Alliance for Clinical Trials in Oncology
OHSU Knight Cancer Institute
Vanderbilt-Ingram Cancer Center
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Mayo Clinic
University of Arkansas
SWOG Cancer Research Network
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)